Navigation Links
MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results

MOUNTAIN VIEW, Calif., Aug. 3 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the second quarter ended June 30, 2009.

The net loss for the quarter ended June 30, 2009 was $5.0 million, compared to $16.5 million during the same period in 2008. The net loss for the first six months of 2009 was $14.9 million, compared to $30.8 million for the first six months of 2008. As of June 30, 2009, MAP Pharmaceuticals had cash, cash equivalents, short-term investments and accounts receivables of $59.9 million.

"We are very pleased that in the first Phase 3 trial for our LEVADEX(TM) migraine therapy, all four primary endpoints were met with statistical significance," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "With these positive results in hand and our recent decision to suspend development of Unit Dose Budesonide (UDB), we are now focusing our efforts on the development of LEVADEX. We believe that LEVADEX has a differentiated profile, with the potential to provide rapid and sustained relief of migraine symptoms, and could offer benefit to many of the approximately 30 million migraine sufferers in the U.S., including many who are not helped by currently available migraine therapies. We look forward to presenting the data from our successful Phase 3 trial of LEVADEX at the 14th Congress of the International Headache Society in September."

Second Quarter and Six Month Financial Results

Revenues for the quarter and six months ended June 30, 2009 were $8.6 million and $16.1 million, respectively, compared to $0 for the same periods in 2008. The collaboration revenue to date in 2009 was due to the amortization of a $40.0 million upfront payment received in February 2009 and reimbursements for UDB-related development expenses, pursuant to MAP Pharmaceuticals' license agreement with AstraZeneca AB. On July 8, 2009, the company received notice from AstraZeneca of the termination of the license agreement, effective immediately. As a result, the remaining unamortized deferred revenue of $33.1 million will be recognized as collaboration revenue in the third quarter of fiscal 2009.

Research and development expenses for the quarter and six months ended June 30, 2009 were $9.6 million and $23.7 million, respectively, compared to $13.0 million and $24.8 million, respectively, for the same periods in 2008. The decreases in research and development expenses were driven primarily by decreases in clinical and other project expenses to support the UDB Phase 3 clinical program, partially offset by increases in clinical and other project expenses to support the LEVADEX Phase 3 clinical program, and in personnel-related expenses to support these clinical programs.

Sales, general and administrative expenses for the quarter and six months ended June 30, 2009 were $3.4 million and $6.2 million, respectively, compared to $3.2 million and $6.3 million, respectively, for the same periods in 2008. For the three months ended June 30, 2009 compared to the same period in 2008, the increase was related primarily to increases in personnel-related expenses, stock-based compensation and other miscellaneous fees.

MAP Pharmaceuticals had cash, cash equivalents and short-term investments as of June 30, 2009 of $54.8 million, compared to $44.7 million as of December 31, 2008. In addition, accounts receivables were $5.1 million at June 30, 2009, compared to $0 at December 31, 2008, due to the collaboration with AstraZeneca.

For the quarter and six months ended June 30, 2009, non-cash share-based compensation and depreciation were approximately $1.7 million and $3.3 million, respectively.

Second Half 2009 Financial Outlook

MAP Pharmaceuticals' cash, cash equivalents, short-term investments and accounts receivables as of June 30, 2009 provide operating capital for at least the next twelve months. MAP Pharmaceuticals currently expects to have lower operating expenses in the second half of 2009 compared to the first half of 2009.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate and future cash usage. Actual results may differ materially from current expectations based on risks and uncertainties affecting the company's business, including, without limitation, risks and uncertainties relating to the following: the enrollment, conduct, completion and reporting of clinical trials, risks related to the failure to achieve favorable clinical outcomes and to have the company's LEVADEX product candidate approved for commercial use. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Annual Report on Form 10-K for the year ended December 31, 2008, as amended, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2009 and available at

CONTACT: Christopher Y. Chai, Chief Financial Officer of MAP Pharmaceuticals, Inc., (650) 386-3107; or media, Nicole Foderaro of Invigorate Communications, (415) 946-1058,

                           MAP PHARMACEUTICALS, INC.
                        (a development stage enterprise)
                                 (In thousands)

                                                             June   December
                                                              30,       31,
                                                             2009      2008
                                                             ----      ----

      Current assets:
        Cash, cash equivalents and short-term
         investments                                      $54,754   $44,710
        Account receivable                                  5,174         -
        Other current assets                                  372       805
                                                              ---       ---

      Total current assets                                 60,300    45,515
      Property and equipment, net                           4,457     5,007
      Other assets                                             28        28
      Restricted cash                                         310       310
                                                              ---       ---

      Total assets                                        $65,095   $50,860
                                                          =======   =======

      Current liabilities:
        Accounts payable and accrued expenses             $12,709   $17,076
        Current portion of debt                             7,025     6,348
        Current portion of deferred revenue                16,552         -
                                                           ------    ------

      Total current liabilities                            36,286    23,424
      Debt, less current portion                           10,890    14,229
      Deferred revenue, less current portion               16,552         -
      Other liabilities                                        74        60
                                                               --        --

      Total liabilities                                    63,802    37,713

      Total stockholders' equity                            1,293    13,147
                                                            -----    ------

      Total liabilities and stockholders' equity          $65,095   $50,860
                                                          =======   =======

                           MAP PHARMACEUTICALS, INC.
                        (a development stage enterprise)
               (In thousands, except share and per share amounts)

                                 Three Months Ended      Six Months Ended
                                      June 30,                June 30,
                                 ------------------      ----------------

                                  2009        2008        2009        2008
                                  ----        ----        ----        ----

    Collaboration revenue       $8,645          $-     $16,129          $-

    Operating expenses:
        Research and
         development             9,628      12,984      23,703      24,799
        Sales, general and
         administrative          3,437       3,165       6,245       6,305
                                 -----       -----       -----       -----

         expenses               13,065      16,149      29,948      31,104

    Loss from
     operations                 (4,420)    (16,149)    (13,819)    (31,104)

    Other income
     (expense), net               (549)       (308)     (1,070)        347
                                   ---         ---       -----         ---

    Net loss                    (4,969)    (16,457)    (14,889)    (30,757)
                                 =====      ======      ======      ======

    Net loss per share
     attributable to
     basic and diluted
                                $(0.24)     $(0.81)      (0.72)     $(1.52)
                                  ====        ====        ====        ====

     common shares used
     in computing net
     loss per share
     attributable to
     basic and diluted
                            20,699,343  20,314,390  20,641,878  20,262,318
                            ==========  ==========  ==========  ==========

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The American Association of ... local poison centers through donations on Tuesday, Dec. 1, 2015. Since 2012, the ... that inspires people to collaborate in improving their local communities and help give ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the Ron ... designed to yield insights into how to detect and treat pancreatic cancer (PC). ... from small, non-coding RNA molecules (ncRNA), genetic material that is present in the blood ...
(Date:11/24/2015)... ... , ... Dr. Rodney E. Willey , has answered a new calling – to relieve ... provides treatment for snoring and sleep apnea through oral appliance therapy. He ... Disorders in the US, one of four in the Illinois area. , Dr. Willey’s ...
(Date:11/24/2015)... ... November 24, 2015 , ... Autism Speaks, the world’s leading ... driven by social media and the generosity of people around the world. On December ... media networks to give – and share the personal stories behind those gifts. ...
(Date:11/24/2015)... ... November 24, 2015 , ... Robert Yeager ... Report . Throughout the past year there have been multiple breakthroughs and challenges as ... this transition, PharmMD has enabled their customers and partners to stay ahead of the ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... LONDON , November 24, 2015 ... PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and ... areas are going to grow at the fastest rates? ... to 2025, assessing data, trends, opportunities and prospects there. ... graphs. Discover the most lucrative areas in the industry ...
(Date:11/24/2015)...  Enova Illumination is pleased to announce a new ... to combine their world class camera and ... of medical visualization: Enova is the first manufacturer of ... and Novocam is the manufacturer of HD ... most powerful battery-operated LED headlight with high-quality point-of-view video ...
(Date:11/24/2015)... Calif. , Nov. 24, 2015 Abaxis, ... manufacturing point-of-care instruments and consumables for the medical, research, ... Taylor , Chief Financial Officer, will present at the ... Tuesday, December 1, 2015 at 11:30 a.m. ET. The ... Palace in New York City . ...
Breaking Medicine Technology: